Octreotide scintigraphy in patients with differentiated thyroid carcinoma : Contribution for patients with negative radioiodine scan

Somatostatin receptor scintigraphy (SRS) was evaluated in 25 differentiated thyroid carcinoma (DTC) patients. All DTC patients had elevated thyroglobulin levels. A total body scan (TBS) was performed 4 and 24 h after injection of indium-111-DTPA-Phe-octreotide. Group 1 included 16 patients with nega...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 1996-07, Vol.81 (7), p.2541-2544
Main Authors: BAUDIN, E, SCHLUMBERGER, M, LUMBROSO, J, TRAVAGLI, J.-P, CAILLOU, B, PARMENTIER, C
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Endocrinopathies
Female
Humans
Indium Radioisotopes
Iodine Radioisotopes
Lymphatic Metastasis
Male
Malignant tumors
Medical sciences
Middle Aged
Octreotide - analogs & derivatives
Pentetic Acid - analogs & derivatives
Radionuclide Imaging
Receptors, Somatostatin - analysis
Thyroglobulin - metabolism
Thyroid Neoplasms - diagnostic imaging
Thyroid Neoplasms - pathology
Thyroid Neoplasms - surgery
Thyroid. Thyroid axis (diseases)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Somatostatin receptor scintigraphy (SRS) was evaluated in 25 differentiated thyroid carcinoma (DTC) patients. All DTC patients had elevated thyroglobulin levels. A total body scan (TBS) was performed 4 and 24 h after injection of indium-111-DTPA-Phe-octreotide. Group 1 included 16 patients with negative 131I TBS; group 2 had 9 patients with positive 131I TBS. SRS results were compared to the results of conventional imaging methods in group 1 and to 131I TBS in group 2. 131I TBS was performed after administration of a therapeutic dose of 131I in all patients except one. SRS was positive in 20 of 25 (80%) patients. In group 1, SRS was positive in 12 of 16 patients; in the 3 patients with no previously known tumor site, SRS visualized one abnormal neck focus of uptake in two. In the other 13 patients, SRS disclosed unknown mediastinal foci in 2, but visualized less organ involvements and a smaller number of tumor sites than conventional imaging methods. In group 2, SRS was positive in 8 of 9 patients and visualized an identical (7 patients) or a smaller number (1 patient) of involved organs than 131I TBS; in 2 patients, SRS allowed the discovery of 1 abdominal and 1 bone tumor site. We suggest than SRS should guide imaging modalities in DTC patients with negative 131I TBS and be an alternative to 131I TBS in DTC patients unable to withdraw T4 treatment.
ISSN:0021-972X
1945-7197
DOI:10.1210/jc.81.7.2541